about
Two drugs are better than one. A short history of combined therapy of ovarian cancerInhibitors of microtubule polymerization- new natural compounds as potential anti-cancer drugsThe role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin.Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.WP 631 and Epo B synergize in SKOV-3 human ovarian cancer cells.Cytotoxicity and induction of apoptosis by formamidinodoxorubicins in comparison to doxorubicin in human ovarian adenocarcinoma cells.Effect of metformin on apoptosis induction in ovarian cancer cells.Identification of the key pathway of oxazolinoanthracyclines mechanism of action in cells derived from human solid tumors.New potential chemotherapy for ovarian cancer - Combined therapy with WP 631 and epothilone B.Doxorubicin-transferrin conjugate triggers pro-oxidative disorders in solid tumor cells.Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death.Epothilone B induces human ovarian cancer OV-90 cell apoptosis via external pathway.Epothilone B induces extrinsic pathway of apoptosis in human SKOV-3 ovarian cancer cells.Pro-apoptotic activity of new analog of anthracyclines--WP 631 in advanced ovarian cancer cell line.Analysis of epothilone B-induced cell death in normal ovarian cells.Activation of apoptotic pathway in normal, cancer ovarian cells by epothilone B.Structural modifications in the sugar moiety as a key to improving the anticancer effectiveness of doxorubicin.The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts.Influence of Pre-Storage Irradiation on the Oxidative Stress Markers, Membrane Integrity, Size and Shape of the Cold Stored Red Blood Cells.The influence of 2-chlorodeoxyadenosine (2-CdA) on the adenine energy charge and glutathione content of human erythrocytes.Damage to the cell antioxidative system in human erythrocytes incubated with idarubicin and glutaraldehyde.Fluorescence anisotropy of membrane fluidity probes in human erythrocytes incubated with anthracyclines and glutaraldehyde.Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells.Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients.The effect of catechol on human peripheral blood mononuclear cells (in vitro study).The interaction of DNR and glutaraldehyde with cell membrane proteins leads to morphological changes in erythrocytes.Erratum to "Molecular mechanism of action of oxazolinoanthracyclines in cells derived from human solid tumors. Part 2" [Toxicol. in Vitro 46 (2018) 323-334].Molecular mechanism of action of oxazolinoanthracyclines in cells derived from human solid tumors. Part 2.ROS production and their influence on the cellular antioxidative system in human erythrocytes incubated with daunorubicin and glutaraldehyde.The combined effect of IDA and glutaraldehyde on the erythrocyte membrane proteins.Therapeutic potential of patupilone in epithelial ovarian cancer and future directions.Hyperglycemia-Associated Dysregulation of O-GlcNAcylation and HIF1A Reduces Anticancer Action of Metformin in Ovarian Cancer Cells (SKOV-3)Novel oxazolinoanthracyclines as tumor cell growth inhibitors-Contribution of autophagy and apoptosis in solid tumor cells death
P50
Q26770477-56F85206-0907-45A4-A188-A956FD0FA5D7Q28081036-0008BF9B-FD82-46F4-BAAC-B3439B7EAFFCQ34012431-A347598B-A8BD-4AC0-AF23-BD0CBE5987B4Q34721579-3866196D-F602-4857-95D4-FD28C804FA8CQ35077223-F2802FD3-8903-471E-B3E5-709FF34B626CQ35538526-6FF446B8-412B-49B9-B661-40B2DB2FCBACQ35761271-DAD601BB-C9F7-498F-8AC1-53B80D6C68D6Q36174296-9DBC6E35-336C-4F1A-877C-E37C9703E756Q38761233-AF9928CC-2932-447B-913F-BE6935AF7D4DQ38816743-7ECD1C7D-1D5D-4BB7-8F2A-D8ACCF97A8ADQ38877024-1F070900-216E-4BEA-B2A3-B98A0C7598C2Q38905653-5B741EA7-DF62-4487-83F3-40F74F47AEB5Q39019602-BC088319-F41A-47A9-B74D-8C05ED76D68DQ39052587-EC6F0700-271F-4CB6-8F0E-77F59CF20280Q39108561-575A580F-5452-421A-9F1B-7EDC26A3F452Q39128446-948BF171-BC41-4E7F-9404-66660B771FD8Q39255455-F6E68A82-27A2-4257-A412-9DC24E79AC37Q40060951-B5264498-C750-43A2-9820-CC0F971FBFE6Q41661613-22A5F371-1BFF-4657-92BC-1A14B7771660Q45164589-C8001ADD-A6AA-4551-93D5-4A70F4A1A3E0Q45985557-F96DAAA0-C013-43C1-8940-A4F05E97B145Q46209568-141712D2-0830-49D9-AEAC-2ABBD95DD64CQ46265632-D25241B9-107B-43E4-AE12-2FCF22228347Q46791821-A71C39BA-8A9C-4519-9AC8-9ABBBD57ACB8Q46796136-80A2279E-7E57-41A1-8B9D-A9D857076A02Q46865176-B47F0359-51F8-4F01-B9F9-2E96A73ACF8EQ50056913-A82E1A45-7EBA-47B7-ADEF-B4B1AA2155F5Q50078289-8411E146-A5FC-42DC-A20B-6B4AAA45E9DBQ50491985-9C17232F-24B8-42E8-AE78-C60D4F8FE59EQ50712329-20B37657-425F-4F60-9B77-6AD6D5BF4923Q53687756-33061B2D-D0DE-48F1-BA2C-2FD05213D02EQ58742476-7E81A281-5622-4EC0-BE89-58C6E3B9A099Q90442986-1ADE854A-2D57-4F25-A17E-C242DD2B01CC
P50
description
Pools onderzoekster
@nl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Agnieszka Marczak
@ast
Agnieszka Marczak
@ca
Agnieszka Marczak
@cs
Agnieszka Marczak
@en
Agnieszka Marczak
@es
Agnieszka Marczak
@gl
Agnieszka Marczak
@hr
Agnieszka Marczak
@hsb
Agnieszka Marczak
@it
Agnieszka Marczak
@nl
type
label
Agnieszka Marczak
@ast
Agnieszka Marczak
@ca
Agnieszka Marczak
@cs
Agnieszka Marczak
@en
Agnieszka Marczak
@es
Agnieszka Marczak
@gl
Agnieszka Marczak
@hr
Agnieszka Marczak
@hsb
Agnieszka Marczak
@it
Agnieszka Marczak
@nl
altLabel
Agnieszka Urszula Marczak
@pl
szwarocka agnieszka
@en
prefLabel
Agnieszka Marczak
@ast
Agnieszka Marczak
@ca
Agnieszka Marczak
@cs
Agnieszka Marczak
@en
Agnieszka Marczak
@es
Agnieszka Marczak
@gl
Agnieszka Marczak
@hr
Agnieszka Marczak
@hsb
Agnieszka Marczak
@it
Agnieszka Marczak
@nl
P214
P106
P1153
55962429900
P1412
P1559
Agnieszka Marczak
@pl
P21
P214
P27
P31
P3124
P496
0000-0003-3439-9032
P734
P7859
viaf-315230124